Group 1 - The A-share market saw a collective low opening on October 31, with the innovative drug concept experiencing a volatile rebound [1] - The Tianhong Innovative Drug ETF (517380) rose by 2.15%, with a trading volume exceeding 10 million yuan, and recorded a net inflow of over 12 million yuan on October 30 [1] - The Biopharmaceutical ETF (159859) increased by 0.72%, with a trading volume exceeding 42 million yuan, and saw a net subscription of over 50 million units during the session [1] Group 2 - The Biopharmaceutical ETF closely tracks the Biopharmaceutical Index, which includes the top 30 stocks in the biopharmaceutical industry based on market capitalization and liquidity [2] - A notification from seven departments, including the National Health Commission, announced that the HPV vaccine will be included in the national immunization program starting November 10, 2025, for girls born after November 10, 2011 [2] - The 2025 National Medical Insurance negotiations began on October 30, introducing a "commercial insurance innovative drug directory" mechanism for the first time [2] Group 3 - Huafu Securities expressed optimism about the innovative drug sector, predicting a significant transformation over the next 5-10 years driven by international expansion, continuous data catalysts, and new product sales [2] - Industrial trends in the innovative drug sector remain positive, with a focus on "innovation + internationalization" [3] - The innovative drug sector's resilience is expected to improve further after short-term adjustments, with a focus on the improving fundamentals of the innovative drug industry chain [3]
HPV疫苗纳入国家免疫规划，创新药ETF天弘（517380）涨超2%、生物医药ETF（159859）盘中获净申购超5000万份
2 1 Shi Ji Jing Ji Bao Dao·2025-10-31 02:32